

Maria Grazia Roncarolo

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7964242/maria-grazia-roncarolo-publications-by-year.pdf>

Version: 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

59
papers

11,354
citations

34
h-index

65
g-index

65
ext. papers

12,824
ext. citations

13
avg, IF

5.65
L-index

#	Paper	IF	Citations
59	The Women of FOCIS: Promoting Equality and Inclusiveness in a Professional Federation of Clinical Immunology Societies.. <i>Frontiers in Immunology</i> , 2022 , 13, 816535	8.4	
58	Co-Expression of FOXP3FL and FOXP3 Δ Isoforms Is Required for Optimal Treg-Like Cell Phenotypes and Suppressive Function. <i>Frontiers in Immunology</i> , 2021 , 12, 752394	8.4	0
57	Lentiviral Mediated Gene Therapy for Pyruvate Kinase Deficiency: Interim Results of a Global Phase 1 Study for Adult and Pediatric Patients. <i>Blood</i> , 2021 , 138, 563-563	2.2	2
56	Engineering Human Invariant Natural Killer T (iNKT) Cells to Overexpress Immunomodulatory Cytokines. <i>Blood</i> , 2021 , 138, 3888-3888	2.2	
55	Engineered type 1 regulatory T cells designed for clinical use kill primary pediatric acute myeloid leukemia cells. <i>Haematologica</i> , 2021 , 106, 2588-2597	6.6	4
54	Alloantigen-specific type 1 regulatory T cells suppress through CTLA-4 and PD-1 pathways and persist long-term in patients. <i>Science Translational Medicine</i> , 2021 , 13, eabf5264	17.5	2
53	The Yin and Yang of Type 1 Regulatory T Cells: From Discovery to Clinical Application. <i>Frontiers in Immunology</i> , 2021 , 12, 693105	8.4	2
52	Development of β globin gene correction in human hematopoietic stem cells as a potential durable treatment for sickle cell disease. <i>Science Translational Medicine</i> , 2021 , 13,	17.5	12
51	BHLHE40 Regulates IL-10 and IFN- Production in T Cells but Does Not Interfere With Human Type 1 Regulatory T Cell Differentiation. <i>Frontiers in Immunology</i> , 2021 , 12, 683680	8.4	0
50	Genome editing of donor-derived T-cells to generate allogeneic chimeric antigen receptor-modified T cells: Optimizing T cell-depleted haploidentical hematopoietic stem cell transplantation. <i>Haematologica</i> , 2021 , 106, 847-858	6.6	18
49	InsB9-23 Gene Transfer to Hepatocyte-Based Combined Therapy Abrogates Recurrence of Type 1 Diabetes After Islet Transplantation. <i>Diabetes</i> , 2021 , 70, 171-181	0.9	1
48	Pre-clinical development and molecular characterization of an engineered type 1 regulatory T-cell product suitable for immunotherapy. <i>Cytotherapy</i> , 2021 , 23, 1017-1028	4.8	1
47	Coexpression of CD163 and CD141 identifies human circulating IL-10-producing dendritic cells (DC-10). <i>Cellular and Molecular Immunology</i> , 2020 , 17, 95-107	15.4	27
46	Gene correction for SCID-X1 in long-term hematopoietic stem cells. <i>Nature Communications</i> , 2019 , 10, 1634	17.4	77
45	Lentiviral haemopoietic stem/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1/2 clinical study. <i>Lancet Haematology</i> , 2019 , 6, e239-e253	14.6	95
44	Gene therapy for primary immunodeficiency. <i>Human Molecular Genetics</i> , 2019 , 28, R15-R23	5.6	31
43	Graft Engineering and Adoptive Immunotherapy: New Approaches to Promote Immune Tolerance After Hematopoietic Stem Cell Transplantation. <i>Frontiers in Immunology</i> , 2019 , 10, 1342	8.4	23

42	Lentiviral Gene Therapy in HSCs Restores Lineage-Specific Foxp3 Expression and Suppresses Autoimmunity in a Mouse Model of IPEX Syndrome. <i>Cell Stem Cell</i> , 2019 , 24, 309-317.e7	18	29
41	Gene Therapy for Adenosine Deaminase Deficiency: A Comprehensive Evaluation of Short- and Medium-Term Safety. <i>Molecular Therapy</i> , 2018 , 26, 917-931	11.7	35
40	Role of human forkhead box P3 in early thymic maturation and peripheral T-cell homeostasis. <i>Journal of Allergy and Clinical Immunology</i> , 2018 , 142, 1909-1921.e9	11.5	12
39	Peanut-specific type 1 regulatory T cells induced in vitro from allergic subjects are functionally impaired. <i>Journal of Allergy and Clinical Immunology</i> , 2018 , 141, 202-213.e8	11.5	20
38	Reprogramming human T cell function and specificity with non-viral genome targeting. <i>Nature</i> , 2018 , 559, 405-409	50.4	367
37	Engineered T Regulatory Type 1 Cells for Clinical Application. <i>Frontiers in Immunology</i> , 2018 , 9, 233	8.4	44
36	APVO210: A Bispecific Anti-CD86-IL-10 Fusion Protein (ADAPTIR) to Induce Antigen-Specific T Regulatory Type 1 Cells. <i>Frontiers in Immunology</i> , 2018 , 9, 881	8.4	12
35	The Biology of T Regulatory Type 1 Cells and Their Therapeutic Application in Immune-Mediated Diseases. <i>Immunity</i> , 2018 , 49, 1004-1019	32.3	123
34	Molecular and functional heterogeneity of IL-10-producing CD4 T cells. <i>Nature Communications</i> , 2018 , 9, 5457	17.4	48
33	Tregopathies: Monogenic diseases resulting in regulatory T-cell deficiency. <i>Journal of Allergy and Clinical Immunology</i> , 2018 , 142, 1679-1695	11.5	65
32	Minimum Information about T Regulatory Cells: A Step toward Reproducibility and Standardization. <i>Frontiers in Immunology</i> , 2017 , 8, 1844	8.4	34
31	IL-10-Engineered Human CD4 Tr1 Cells Eliminate Myeloid Leukemia in an HLA Class I-Dependent Mechanism. <i>Molecular Therapy</i> , 2017 , 25, 2254-2269	11.7	28
30	In Vivo Tracking of Human Hematopoiesis Reveals Patterns of Clonal Dynamics during Early and Steady-State Reconstitution Phases. <i>Cell Stem Cell</i> , 2016 , 19, 107-119	18	130
29	Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency. <i>Blood</i> , 2016 , 128, 45-54	2.2	133
28	B-cell reconstitution after lentiviral vector-mediated gene therapy in patients with Wiskott-Aldrich syndrome. <i>Journal of Allergy and Clinical Immunology</i> , 2015 , 136, 692-702.e2	11.5	34
27	In vivo tracking of T cells in humans unveils decade-long survival and activity of genetically modified T memory stem cells. <i>Science Translational Medicine</i> , 2015 , 7, 273ra13	17.5	114
26	Hurdles in therapy with regulatory T cells. <i>Science Translational Medicine</i> , 2015 , 7, 304ps18	17.5	114
25	Insulin B chain 9-23 gene transfer to hepatocytes protects from type 1 diabetes by inducing Ag-specific FoxP3+ Tregs. <i>Science Translational Medicine</i> , 2015 , 7, 289ra81	17.5	45

24	B-cell development and functions and therapeutic options in adenosine deaminase-deficient patients. <i>Journal of Allergy and Clinical Immunology</i> , 2014 , 133, 799-806.e10	11.5	27
23	Tr1 cells and the counter-regulation of immunity: natural mechanisms and therapeutic applications. <i>Current Topics in Microbiology and Immunology</i> , 2014 , 380, 39-68	3.3	161
22	Regulatory T cells: recommendations to simplify the nomenclature. <i>Nature Immunology</i> , 2013 , 14, 307-8	19.1	433
21	Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. <i>Science</i> , 2013 , 341, 1233-158	33.3	837
20	Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. <i>Science</i> , 2013 , 341, 1233-151	33.3	755
19	Liver gene therapy by lentiviral vectors reverses anti-factor IX pre-existing immunity in haemophilic mice. <i>EMBO Molecular Medicine</i> , 2013 , 5, 1684-97	12	49
18	Human IL2RA null mutation mediates immunodeficiency with lymphoproliferation and autoimmunity. <i>Clinical Immunology</i> , 2013 , 146, 248-61	9	141
17	Immune responses in liver-directed lentiviral gene therapy. <i>Translational Research</i> , 2013 , 161, 230-40	11	15
16	CD4+ T cells from IPEX patients convert into functional and stable regulatory T cells by FOXP3 gene transfer. <i>Science Translational Medicine</i> , 2013 , 5, 215ra174	17.5	89
15	The cellular and molecular mechanisms of immuno-suppression by human type 1 regulatory T cells. <i>Frontiers in Immunology</i> , 2012 , 3, 30	8.4	120
14	Rapamycin combined with anti-CD45RB mAb and IL-10 or with G-CSF induces tolerance in a stringent mouse model of islet transplantation. <i>PLoS ONE</i> , 2011 , 6, e28434	3.7	33
13	Th17 cells express interleukin-10 receptor and are controlled by Foxp3 [?] and Foxp3 ⁺ regulatory CD4 ⁺ T cells in an interleukin-10-dependent manner. <i>Immunity</i> , 2011 , 34, 554-65	32.3	441
12	Killing of myeloid APCs via HLA class I, CD2 and CD226 defines a novel mechanism of suppression by human Tr1 cells. <i>European Journal of Immunology</i> , 2011 , 41, 1652-62	6.1	97
11	Hepatocyte-targeted expression by integrase-defective lentiviral vectors induces antigen-specific tolerance in mice with low genotoxic risk. <i>Hepatology</i> , 2011 , 53, 1696-707	11.2	108
10	Induction of anergic allergen-specific suppressor T cells using tolerogenic dendritic cells derived from children with allergies to house dust mites. <i>Journal of Allergy and Clinical Immunology</i> , 2010 , 125, 727-36	11.5	41
9	Molecular and functional characterization of allogantigen-specific anergic T cells suitable for cell therapy. <i>Haematologica</i> , 2010 , 95, 2134-43	6.6	51
8	Evidence for long-term efficacy and safety of gene therapy for Wiskott-Aldrich syndrome in preclinical models. <i>Molecular Therapy</i> , 2009 , 17, 1073-82	11.7	66
7	Loss of mismatched HLA in leukemia after stem-cell transplantation. <i>New England Journal of Medicine</i> , 2009 , 361, 478-88	59.2	337

6	Type 1 regulatory T cells are associated with persistent split erythroid/lymphoid chimerism after allogeneic hematopoietic stem cell transplantation for thalassemia. <i>Haematologica</i> , 2009 , 94, 1415-26	6.6	53
5	Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. <i>Immunological Reviews</i> , 2006 , 212, 28-50	11.3	966
4	Defective regulatory and effector T cell functions in patients with FOXP3 mutations. <i>Journal of Clinical Investigation</i> , 2006 , 116, 1713-22	15.9	383
3	Differentiation of Tr1 cells by immature dendritic cells requires IL-10 but not CD25+CD4+ Tr cells. <i>Blood</i> , 2005 , 105, 1162-9	2.2	401
2	Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. <i>Science</i> , 2002 , 296, 2410-3	33.3	947
1	A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. <i>Nature</i> , 1997 , 389, 737-42	50.4	3084